Lexicon Pharmaceuticals Inc recorded a cumulative net loss of $-61 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 123 other companies achieving higher income per employee. While Lexicon Pharmaceuticals Inc 's total ranking has deteriorated compared to the previous quarter from 322 to 3338.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LXRX Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-754,531	-322,099	-621,506	-846,642	-1,489,136
LXRX's Total Ranking	# 3338	# 322	# 2161	# 3040	#
Seq. Net Income Change	-	-	-	-	-

LXRX Company Profile >> Back to LXRX Efficiency Comparisons >> Compare LXRX Net Income per Employee to its Competitors

LXRX Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 124
Healthcare Sector	# 405
Overall Market	# 3338

Net Income per Employee Statistics
High	Average	Low
$ 2,030,741	$ -1,106,725	$ -2,671,519
(Sep 30 2019)		(Sep 30 2024)

News about Lexicon Pharmaceuticals Inc Income per employee

Lexicon Pharmaceuticals Announces $250 Million Private Placement of Equity Securities

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has recently revealed that it has entered into a securities purchase agreement for a private investment in public equity financing. The company expects to amass approximately $250 million in gross proceeds through this financing round, which will strengthen its financial position. The placement will involve the sale of approximately 2.3 million shares of Series A Convertible Preferred Stock, priced at $108.50 per share. This stock will be convertible into approximately 115.2 million shares of Lexicon s common stock.
Facts:
1. Lexicon Pharmaceuticals, Inc. has entered into a securities purchase agreement for a private investment in public equity financing.
2. The financing round is expected to generate around $250 million in gross proceeds.
3. The sale will involve approximately 2.3 million shares of Series A Convertible Preferred Stock.
4. The price per share of the preferred stock is set at $108.50.
5. The preferred stock can be converted into approximately 115.2 million shares of Lexicon s common stock.
6. The investment will be made by a select group of accredited investors.
7. The cumulative net loss for Lexicon Pharmaceuticals Inc in the last 12 months, ending in the third quarter of 2023, was recorded at $-158 million.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-08T13:54:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.